Biogen has entered a collaboration worth up to $411 million with TrimTech Therapeutics to develop protein degraders for neurodegenerative diseases. The deal includes up to $32 million in upfront and research milestone payments, while the larger headline value depends on additional milestones later in development.

In exchange, Biogen receives an exclusive global license to small molecule protein degraders generated using TrimTech’s technology. The strategic point is less the upfront economics than Biogen’s choice of modality: the company is placing a neurodegeneration bet on a newer degradation platform rather than relying only on the better-known antibody and small-molecule playbooks already common in the field.

The Technology

Cambridge, U.K.-based TrimTech uses a platform built on the E3-ligase TRIM21 to clear disease-causing protein aggregates. Its degrader approaches include bispecific chimeric molecules called TRIMTAC and a mutual binding facilitator called TRIMGLUE.

Those approaches may provide an alternative to the more common bivalent degraders known as PROTACs. TrimTech has identified Huntington’s, Alzheimer’s and Parkinson’s as potential targets for its platform.

Why It Fits Biogen

Those disease areas align with Biogen’s existing neurodegenerative R&D focus, particularly in Alzheimer’s. The company and Eisai have brought two drugs over the regulatory finish line in recent years, including the monoclonal antibody Leqembi.

For Biogen, the collaboration adds earlier-stage scientific optionality in an area where removing disease-causing protein aggregates remains a central therapeutic goal. For TrimTech, the agreement is a validation event after a year in which Johnson & Johnson, Eli Lilly and Pfizer participated in a $47 million seed round.

Founded in 2023, TrimTech was also named to Fierce Biotech’s Fierce 15 in 2025. The broader industry signal is that large drugmakers are still willing to fund differentiated protein degradation platforms when they offer a distinct mechanistic angle in hard-to-treat diseases, even before clinical proof has been established.